Cunningham D, Gazet J C, Ford H T, Coombes R C
St. George's Hospital, London, England.
Cancer Treat Rep. 1987 Nov;71(11):1091-2.
We have treated 15 patients with locally advanced or metastatic breast cancer using the synthetic 19-norsteroid gestrinone (2.5 mg orally every 3 days). All patients had assessable disease and endocrine-sensitive tumors, as defined by a previous positive response to endocrine therapy. There were no objective responses. Six patients had disease stabilization and nine had progressive disease on treatment. Seven patients were given endocrine therapy after gestrinone and three have responded. Gestrinone has no significant antitumor activity in hormone-sensitive breast cancer. This, however, does not preclude its use in benign breast disease, particularly since other agents used for benign breast disease can mask occult primary carcinoma.
我们使用合成的19-去甲甾体孕三烯酮（每3天口服2.5毫克）治疗了15例局部晚期或转移性乳腺癌患者。所有患者均有可评估的疾病，且肿瘤对内分泌敏感，定义为先前对内分泌治疗有阳性反应。未观察到客观缓解。6例患者疾病稳定，9例患者在治疗过程中疾病进展。7例患者在服用孕三烯酮后接受了内分泌治疗，其中3例有反应。孕三烯酮在激素敏感性乳腺癌中没有显著的抗肿瘤活性。然而，这并不排除其在良性乳腺疾病中的应用，特别是因为用于良性乳腺疾病的其他药物可能会掩盖隐匿性原发性癌。
